Stoke Therapeutics, Inc. (STOK) Bundle
Understanding Stoke Therapeutics, Inc. (STOK) Revenue Streams
Understanding Stoke Therapeutics, Inc.’s Revenue Streams
Revenue for the nine months ended September 30, 2024: $13.9 million
Revenue for the nine months ended September 30, 2023: $6.0 million
Year-over-year revenue growth: An increase of $7.9 million, representing a growth rate of approximately 132%.
Revenue for the three months ended September 30, 2024: $4.9 million
Revenue for the three months ended September 30, 2023: $3.3 million
Year-over-year revenue growth: An increase of $1.6 million, representing a growth rate of approximately 48%.
Breakdown of Primary Revenue Sources
Revenue is primarily generated from satisfying contractual obligations of the collaboration and licensing agreement with Acadia Pharmaceuticals, Inc.
Contribution of Different Business Segments to Overall Revenue
| Revenue Source | 2024 Revenue ($ million) | 2023 Revenue ($ million) | Growth Rate (%) |
|---|---|---|---|
| Collaboration and Licensing Agreement | 13.9 | 6.0 | 132 |
Analysis of Significant Changes in Revenue Streams
The substantial increase in revenue is attributed to the enhanced collaboration with Acadia Pharmaceuticals, which has resulted in higher contractual payments. The revenue growth reflects successful advancements in research and development activities leading to increased recognition of revenue from collaborations.
Total Operating Expenses for the nine months ended September 30, 2024: $101.7 million
Total Operating Expenses for the nine months ended September 30, 2023: $91.2 million
Net Loss for the nine months ended September 30, 2024: $(78.5 million)
Net Loss for the nine months ended September 30, 2023: $(77.7 million)
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate can be summarized as follows:
| Period | Revenue ($ million) | Growth Rate (%) |
|---|---|---|
| Q3 2024 | 4.9 | 48 |
| YTD September 2024 | 13.9 | 132 |
A Deep Dive into Stoke Therapeutics, Inc. (STOK) Profitability
A Deep Dive into Stoke Therapeutics, Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the company reported revenue of $13.9 million, resulting in a gross profit margin of approximately 10%. In comparison, for the nine months ended September 30, 2023, the revenue was $6.0 million, indicating a gross profit margin of approximately 8%.
Operating Profit Margin: The loss from operations for the nine months ended September 30, 2024, was $(87.7) million, leading to an operating profit margin of -628%. For the same period in 2023, the loss from operations was $(85.2) million, resulting in an operating profit margin of -1,426%.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $(78.5) million, yielding a net profit margin of -563%. This is slightly worse than the nine months ended September 30, 2023, where the net loss was $(77.7) million, resulting in a net profit margin of -1,297%.
Trends in Profitability Over Time
Revenue Growth: Revenue increased from $5.98 million in the nine months ended September 30, 2023, to $13.94 million in the same period of 2024, marking a growth of 132%.
Operating Expenses Trends: Total operating expenses rose from $91.2 million in 2023 to $101.7 million in 2024, a change of approximately 11.9%.
Comparison of Profitability Ratios with Industry Averages
Industry Comparison: The average gross profit margin in the biotechnology sector is approximately 70%, while the operating and net profit margins typically range from -20% to -50% for clinical-stage companies. The company's margins significantly deviate from these averages, reflecting its early-stage development status and high R&D expenses.
Analysis of Operational Efficiency
Cost Management: Research and development expenses for the nine months ended September 30, 2024, were $65.7 million, compared to $60.5 million in 2023, representing an increase of about 12%. General and administrative expenses also saw an increase from $30.7 million in 2023 to $36.0 million in 2024, an increase of 17%.
| Metric | 2024 | 2023 | Change (%) |
|---|---|---|---|
| Revenue | $13.94 million | $5.98 million | 132% |
| Gross Profit Margin | 10% | 8% | 25% |
| Operating Profit Margin | -628% | -1,426% | 56% (improvement) |
| Net Profit Margin | -563% | -1,297% | 56% (improvement) |
| R&D Expenses | $65.7 million | $60.5 million | 12% |
| G&A Expenses | $36.0 million | $30.7 million | 17% |
Gross Margin Trends: The gross margin has improved slightly year-over-year, indicative of better revenue generation relative to costs. However, the operational losses remain substantial, primarily driven by high R&D expenditures.
Debt vs. Equity: How Stoke Therapeutics, Inc. (STOK) Finances Its Growth
Debt vs. Equity: How Stoke Therapeutics, Inc. Finances Its Growth
Debt Levels:
As of September 30, 2024, the total liabilities of the company stood at $293.3 million. The breakdown of the debt structure includes long-term and short-term obligations, with operating lease obligations amounting to $5.9 million due in the next fiscal periods.
Debt-to-Equity Ratio:
The debt-to-equity ratio is calculated by dividing total liabilities by total stockholders' equity. As of September 30, 2024, the equity was approximately $232.1 million, resulting in a debt-to-equity ratio of approximately 1.26. This ratio indicates a higher reliance on debt compared to equity financing, compared to the industry average of approximately 0.8.
Recent Debt Issuances:
In April 2024, the company completed a public offering, issuing 5,555,557 shares of common stock at a price of $13.50 per share, raising net proceeds of $119.9 million. This offering was part of a strategy to bolster its equity base and reduce reliance on debt financing.
Credit Ratings:
The company has not received a formal credit rating as it primarily operates in the clinical-stage sector with ongoing losses. The lack of earnings and profitability may impact future credit ratings.
Balancing Debt and Equity Financing:
The company has historically financed its operations primarily through equity offerings, with a total of $671.6 million raised since inception through various means including common stock and convertible notes. The cash balance as of September 30, 2024, was $269.2 million, indicating a robust liquidity position.
| Financial Metric | Value |
|---|---|
| Total Liabilities | $293.3 million |
| Total Equity | $232.1 million |
| Debt-to-Equity Ratio | 1.26 |
| Net Proceeds from Recent Offering | $119.9 million |
| Cash and Cash Equivalents | $269.2 million |
Assessing Stoke Therapeutics, Inc. (STOK) Liquidity
Assessing Liquidity and Solvency
As of September 30, 2024, the liquidity position of the company can be summarized as follows:
- Current Ratio: 5.82
- Quick Ratio: 5.82
Both the current and quick ratios indicate a strong liquidity position, suggesting that the company has sufficient short-term assets to cover its short-term liabilities.
Working Capital Trends
The working capital as of September 30, 2024, is calculated as follows:
| Current Assets (in thousands) | Current Liabilities (in thousands) | Working Capital (in thousands) |
|---|---|---|
| $269,200 | $49,865 | $219,335 |
The working capital has increased significantly compared to prior periods, indicating improved short-term financial health.
Cash Flow Statements Overview
The cash flow statements for the nine months ended September 30, 2024, show the following trends:
| Cash Flow Activities (in thousands) | 2024 | 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | $(63,658) | $(60,418) |
| Net Cash Provided by Investing Activities | $(108,294) | $91,175 |
| Net Cash Provided by Financing Activities | $130,526 | $45,664 |
| Net (Decrease) Increase in Cash | $(41,426) | $76,421 |
The cash flow from operating activities shows a significant outflow, which is typical for companies in the development stage. However, financing activities have provided substantial inflows, indicating ongoing support for operations.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company had:
- Cash, Cash Equivalents, and Marketable Securities: $269.2 million
- Accumulated Deficit: $(480.3) million
- Net Loss for Nine Months: $(78.5) million
Despite the accumulated deficit and ongoing losses, the substantial cash reserves provide a buffer against liquidity concerns and facilitate continued investment in research and development activities.
Is Stoke Therapeutics, Inc. (STOK) Overvalued or Undervalued?
Valuation Analysis
In assessing whether the company is overvalued or undervalued, we will examine key financial ratios, stock price trends, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The P/E ratio for the company is currently N/A. This is primarily due to the company reporting a net loss for the last several years, which renders the P/E ratio ineffective for valuation.
Price-to-Book (P/B) Ratio
The P/B ratio stands at 1.26 as of September 30, 2024. This is calculated based on a book value of equity of $232.1 million and total shares outstanding of 52,941,191.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is also N/A as the company has not yet generated positive EBITDA, reflecting ongoing operational losses.
Stock Price Trends
Over the last 12 months, the stock price has experienced significant volatility. The stock was priced at approximately $7.00 one year ago and has risen to around $13.50 following a public offering in April 2024. The following table summarizes the stock price movement:
| Date | Stock Price |
|---|---|
| April 2023 | $7.00 |
| July 2023 | $8.50 |
| October 2023 | $10.00 |
| January 2024 | $12.00 |
| April 2024 | $13.50 |
Dividend Yield and Payout Ratios
The company does not currently pay a dividend, resulting in a dividend yield of 0%. There are no payout ratios to report as no dividends have been distributed.
Analyst Consensus on Stock Valuation
The consensus among analysts is to maintain a "Hold" rating on the stock. The average target price set by analysts for the next 12 months is approximately $12.50, indicating a potential downside from the current price.
Key Financial Metrics Summary
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 1.26 |
| EV/EBITDA Ratio | N/A |
| Stock Price (Current) | $13.50 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
| Average Target Price | $12.50 |
Key Risks Facing Stoke Therapeutics, Inc. (STOK)
Key Risks Facing Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. faces several internal and external risks impacting its financial health. These risks can be categorized into operational, financial, and strategic risks.
Operational Risks
The company has incurred net losses since its inception, with net losses of $26.4 million and $24.5 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024, net losses were $78.5 million, compared to $77.7 million for the same period in 2023. As of September 30, 2024, the accumulated deficit stands at $480.3 million.
Financial Risks
As of September 30, 2024, the company had $269.2 million in cash, cash equivalents, and marketable securities. However, the need for additional funding is critical, as the company expects to continue incurring significant expenses related to research and development, clinical testing, and regulatory compliance. The company has indicated that it will require substantial future capital to complete planned preclinical and clinical development.
Market Conditions
The ability to raise additional funds may be adversely affected by potential worsening global macroeconomic conditions, including inflation, changing interest rates, and instability in the global banking system. If market conditions do not improve, the company may struggle to secure necessary financing.
Regulatory Risks
Regulatory risks are also significant, as the company must navigate complex FDA approval processes for its product candidates. The removal of the partial clinical hold on zorevunersen is a positive development; however, any future regulatory setbacks could delay product timelines and increase costs.
Competition Risks
Competition within the biotechnology sector is fierce, with numerous companies developing similar therapies. The ability to successfully differentiate its product offerings from those of competitors is crucial for maintaining market position and attracting investment.
Mitigation Strategies
To mitigate these risks, Stoke Therapeutics plans to continue raising capital through equity offerings, and collaborations, and may consider debt financing if necessary. The company also aims to manage its operational costs carefully while advancing its clinical programs.
| Risk Type | Details | Financial Impact |
|---|---|---|
| Operational Risks | Net losses since inception; high R&D costs | Accumulated deficit of $480.3 million |
| Financial Risks | Need for additional funding | Cash reserves of $269.2 million |
| Market Conditions | Potential global economic downturns | Difficulty in raising capital |
| Regulatory Risks | FDA approval processes | Delays in product timelines |
| Competition Risks | Fierce competition in the biotech sector | Pressure on market share and revenue potential |
Future Growth Prospects for Stoke Therapeutics, Inc. (STOK)
Future Growth Prospects for Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) is positioned for considerable growth driven by several key factors:
Key Growth Drivers
- Product Innovations: The company is advancing its lead candidate, zorevunersen, which has recently received progress in clinical trials, as the FDA lifted the partial clinical hold on higher doses. This product is aimed at treating Dravet Syndrome, a severe form of epilepsy.
- Market Expansion: Stoke Therapeutics is actively seeking to expand its market presence through ongoing clinical trials and potential partnerships that could enhance its distribution capabilities.
- Acquisitions and Collaborations: The collaboration with Acadia Pharmaceuticals is expected to generate significant revenue through licensing agreements, contributing to future growth.
Future Revenue Growth Projections
Revenue for the nine months ended September 30, 2024, was $13.9 million, a substantial increase from $5.9 million for the same period in 2023. This growth reflects a rise of $7.9 million year-over-year, primarily from revenue generated through collaboration and licensing agreements.
Earnings Estimates
For the third quarter of 2024, the company reported revenue of $4.9 million, compared to $3.3 million in the third quarter of 2023. The increase of $1.6 million indicates a positive trend in earnings, driven by the ongoing development of its product pipeline.
Strategic Initiatives and Partnerships
Stoke Therapeutics completed a public offering in April 2024, raising $119.9 million in net proceeds. This capital will enable the company to fund ongoing research, clinical trials, and potential commercialization efforts for its product candidates.
Competitive Advantages
- Proprietary Technology: The TANGO (Targeted Augmentation of Nuclear Gene Output) platform provides a unique approach to developing antisense oligonucleotides (ASOs), which can selectively target and upregulate protein expression.
- Strong Financial Position: As of September 30, 2024, the company holds $269.2 million in cash, cash equivalents, and marketable securities, which is expected to fund operations through at least the end of 2025.
Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2024, were $65.7 million, reflecting an increase from $60.5 million in the same period of 2023. The allocation of these expenses is primarily directed towards clinical trials and the development of its lead product candidates:
| Program | 2024 Expenses (in thousands) | 2023 Expenses (in thousands) |
|---|---|---|
| Zorevunersen | $22,357 | $19,692 |
| STK-002 | $4,531 | $5,316 |
| SYNGAP1 | $922 | $165 |
| MECP2 | $820 | $678 |
The increase in expenses is primarily due to heightened investment in personnel-related costs and third-party services related to ongoing clinical trials.
Conclusion
Stoke Therapeutics is on a path of significant growth potential through innovative products, strategic partnerships, and a robust financial foundation, positioning itself favorably in the biotechnology sector.
Stoke Therapeutics, Inc. (STOK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Stoke Therapeutics, Inc. (STOK) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Stoke Therapeutics, Inc. (STOK)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Stoke Therapeutics, Inc. (STOK)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.